A Dose Response Study of CTS-1027 in Hepatitis C Patients

Trial Profile

A Dose Response Study of CTS-1027 in Hepatitis C Patients

Phase of Trial: Phase II

Latest Information Update: 14 Sep 2010

At a glance

  • Drugs CTS 1027 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Conatus Pharmaceuticals
  • Most Recent Events

    • 18 Apr 2010 Results presented at the 45th Annual Meeting of the European Association for the Study of the Liver.
    • 22 Jan 2010 Actual end date (July 2009) added as reported by ClinicalTrials.gov.
    • 22 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top